clinical trial · NCT06726161
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
RayzeBio, Inc.·phase2·recruiting·n = 590
Hepatocellular Carcinoma (HCC)RYZ811RYZ801
brief summary
Phase 1/2 randomized, controlled, open-label trial of theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to identify and treat subjects with GPC3+ unresectable hepatocellular carcinoma (HCC)
started
Sep 5, 2025
primary completion
Jun 1, 2030
completion
Jun 1, 2031
last updated
Apr 13, 2026
official title
Phase 1/2 Randomized, Controlled, Open-label Trial of Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ Unresectable Hepatocellular Carcinoma (HCC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol